Investigation of germline VHL variants in Iranian patients with retinal capillary hemangioblastoma and genotype-phenotype analysis

References

• Shuin T, Yao M, Shinohara N, Yamasaki I, Tamura K. Clinical status of Von Hippel-Lindau disease associated pheochromocytoma in Japan: a national epidemiologic survey. Nihon Hinyokika Gakkai Zasshi. 2012;103(3):557–61. doi:10.5980/jpnjurol.103.557.
   PubMedGoogle Scholar
• Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55–64. doi:10.1038/nrc3844.
   PubMed Web of Science ®Google Scholar
• Maher ER, Neumann HP, Richard S. von Hippel–Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19(6):617–23. doi:10.1038/ejhg.2010.175.
   PubMed Web of Science ®Google Scholar
• Chittiboina P, Lonser RR. von Hippel–Lindau disease. Handb Clin Neurol. 2015;132:139–56.
   PubMedGoogle Scholar
• Maher ER, Kaelin JW. von Hippel-Lindau Disease. Medicine. 1997;76(6):381–91. doi:10.1097/00005792-199711000-00001.
   PubMed Web of Science ®Google Scholar
• Ordookhanian C, Kaloostian PE, Ghostine SS, Spiess PE, Etame AB. Management strategies and outcomes for VHL-related craniospinal hemangioblastomas. J Kidney Cancer VHL. 2017;4(3):37. doi:10.15586/jkcvhl.2017.90.
   PubMedGoogle Scholar
• O’Brien F, Danapal M, Jairam S, Lalani A, Cunningham J, Morrin M, McNally S, Donovan MG, Little D, Tuthill A, et al. Manifestations of Von Hippel Lindau syndrome: a retrospective national review. QJM Int J Med. 2014;107(4):291–96. doi:10.1093/qjmed/hct249.
   PubMed Web of Science ®Google Scholar
• Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A review of Von Hippel-Lindau syndrome. J Kidney Cancer VHL. 2017;4(3):20. doi:10.15586/jkcvhl.2017.88.
   PubMedGoogle Scholar
• Kreusel K-M, Bechrakis NE, Krause L, Neumann HP, Foerster MH. Retinal angiomatosis in von Hippel–Lindau disease: a longitudinal ophthalmologic study. Ophthalmology. 2006;113(8):1418–24. doi:10.1016/j.ophtha.2006.02.059.
   PubMed Web of Science ®Google Scholar
• Decker J, Neuhaus C, Macdonald F, Brauch H, Maher ER. Clinical utility gene card for: undefined Hippel–Lindau (VHL). Eur J Hum Genet. 2014;22(4):572. doi:10.1038/ejhg.2013.180.
   Web of Science ®Google Scholar
• Ruppert MD, Gavin M, Mitchell KT, Peiris AN. Ocular manifestations of von Hippel-Lindau disease. Cureus. 2019;11(8). doi:10.7759/cureus.5319.
   Web of Science ®Google Scholar
• Mishra P, Pal S, Kanaujia V, Sharma K. Retinal capillary hemangioblastoma associated with retinochoroidal coloboma in Von Hippel-Lindau disease. Indian J Ophthalmol. 2019;67(5):688–90. doi:10.4103/ijo.IJO_1564_18.
   PubMed Web of Science ®Google Scholar
• Wittebol-Post D, Hes F, Lips C. The eye in von Hippel-Lindau disease. Long-term follow-up of screening and treatment: recommendations. J Intern Med. 1998;243(6):555–61. doi:10.1046/j.1365-2796.1998.00338.x.
   PubMed Web of Science ®Google Scholar
• Nielsen SM, Rhodes L, Blanco IG, Chung WK, Eng C, Maher E, Richard, S, Giles RH, editors. Von Hippel-Lindau Disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. American Society of Clinical Oncology; 2016
   Google Scholar
• Stebbins CE, Kaelin WG, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science. 1999;284(5413):455–61. doi:10.1126/science.284.5413.455.
   PubMed Web of Science ®Google Scholar
• Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Nat Acad Sci. 1996;93(20):10595–99. doi:10.1073/pnas.93.20.10595.
   PubMed Web of Science ®Google Scholar
• Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22(24):4991–5004. doi:10.1200/JCO.2004.05.061.
   PubMed Web of Science ®Google Scholar
• Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH. von Hippel-Lindau Disease. Lancet. 2003;361(9374):2059–67. doi:10.1016/S0140-6736(03)13643-4.
   PubMed Web of Science ®Google Scholar
• Tarade D, Ohh M. The HIF and other quandaries in VHL disease. Oncogene. 2018;37(2):139–47. doi:10.1038/onc.2017.338.
   PubMed Web of Science ®Google Scholar
• Sambrook J, Fritsch E, Maniatis T. Molecular cloning: a laboratory manual. 2. Cold Spring Harbor, NY: Cold spring harbor laboratory press; 1989.
   Google Scholar
• Feldman DE, Thulasiraman V, Ferreyra RG, Frydman J. Formation of the VHL–elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. Mol Cell. 1999;4(6):1051–61. doi:10.1016/S1097-2765(00)80233-6.
   PubMed Web of Science ®Google Scholar
• Melville MW, McClellan AJ, Meyer AS, Darveau A, Frydman J. The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex. Mol Cell Biol. 2003;23(9):3141–51. doi:10.1128/MCB.23.9.3141-3151.2003.
   PubMed Web of Science ®Google Scholar
• Wong WT, Agrón E, Coleman HR, Reed GF, Csaky K, Peterson J, Glenn G, Linehan WM, Albert P, Chew EY. Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis. Arch Ophthalmol. 2007;125(2):239–45. doi:10.1001/archopht.125.2.239.
   PubMedGoogle Scholar
• Lee J-S, Lee J-H, Lee KE, Kim JH, Hong JM, Ra EK, Seo SH, Lee SJ, Kim MJ, Park SS, et al. Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: hIF-α binding site missense mutations elevate age-specific risk for CNS hemangioblastoma. BMC Med Genet. 2016;17(1):1–8. doi:10.1186/s12881-016-0306-2.
   PubMedGoogle Scholar
• Nordstrom‐o’Brien M, van der Luijt RB, van Rooijen E, van den Ouweland AM, Majoor‐krakauer DF, Lolkema MP, van Brussel, A, Voest, EE, Giles, RH. Genetic analysis of von Hippel‐Lindau disease. Hum Mutat. 2010;31(5):521–37. doi:10.1002/humu.21219.
   PubMed Web of Science ®Google Scholar
• Mettu P, Agrón E, Samtani S, Chew EY, Wong WT. Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype. Invest Ophthalmol Visual Sci. 2010;51(9):4464–70. doi:10.1167/iovs.10-5223.
   PubMed Web of Science ®Google Scholar
• Liu S-J, Wang J-Y, Peng S-H, Li T, Ning X-H, Hong B-A, Liu J-Y, Wu P-J, Zhou B-W, Zhou J-C, et al. Genotype and phenotype correlation in von Hippel–Lindau disease based on alteration of the HIF-α binding site in VHL protein. Genet Med. 2018;20(10):1266–73. doi:10.1038/gim.2017.261.
   PubMed Web of Science ®Google Scholar
• Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet. 2001;10(10):1029–38. doi:10.1093/hmg/10.10.1029.
   PubMed Web of Science ®Google Scholar
• Miller F, Kentsis A, Osman R, Pan Z-Q. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL· hypoxia-inducible transcription factor-1α complex. J Biol Chem. 2005;280(9):7985–96. doi:10.1074/jbc.M413160200.
   PubMed Web of Science ®Google Scholar
• Cingoz S, van der Luijt R, Kurt E, Apaydin M, Akkol I, Ozgen MH. A novel missense mutation (N78D) in a family with von Hippel–Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts. Fam Cancer. 2013;12(1):111–17. doi:10.1007/s10689-012-9586-7.
   PubMed Web of Science ®Google Scholar
• Hwang S, Ku CR, Lee JI, Hur KY, Lee M-S, Lee C-H, Koo KY, Lee J-S, Rhee Y. Germline mutation of Glu70Lys is highly frequent in Korean patients with von Hippel–Lindau (VHL) disease. J Hum Genet. 2014;59(9):488–93. doi:10.1038/jhg.2014.61.
   PubMed Web of Science ®Google Scholar
• Sgambati M, Stolle C, Choyke P, Walther M, Zbar B, Linehan W, Glenn GM. Mosaicism in von Hippel–Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet. 2000;66(1):84–91. doi:10.1086/302726.
   PubMed Web of Science ®Google Scholar
• Wu P, Zhang N, Wang X, Ning X, Li T, Bu D, Gong K. Family history of von Hippel–Lindau disease was uncommon in Chinese patients: suggesting the higher frequency of de novo mutations in VHL gene in these patients. J Hum Genet. 2012;57(4):238–43. doi:10.1038/jhg.2012.10.
   PubMed Web of Science ®Google Scholar
• Shen H, Huang H, Luo K, Yi Y, Shi X. Two different pathogenic gene mutations coexisted in the same hereditary spherocytosis family manifested with heterogeneous phenotypes. BMC Med Genet. 2019;20(1):1–7. doi:10.1186/s12881-019-0826-7.
   PubMedGoogle Scholar